Why Is NEOGENOMICS INC (NEO) Stock Up Today?

NEO stock surged 13.24% to $19.67 in early trading on Wednesday, driven by a recent regulatory development and a revised analyst rating. The healthcare diagnostics firm saw its RaDaR ST Molecular Residual Disease Assay gain expanded coverage from CMS’ MolDX, now including immunotherapy monitoring for late-stage solid tumor patients. This development, combined with a price target increase from Needham, contributed to the sharp intraday rally.

What Happened

The stock opened at $17.55, a 1.0% gap up from the prior close, and climbed steadily throughout the session. At 11:15 AM ET, it hit a session high of $19.68, a new 52-week high. The move followed news that the Centers for Medicare & Medicaid Services (CMS) expanded coverage for NeoGenomics’ RaDaR ST assay, a development that could increase demand for the test and broaden its use in cancer care. Additionally, Needham raised its price target for the stock to $19, maintaining a Buy rating. These updates, coupled with a broader healthcare sector rally, fueled investor interest.

What The Data Shows

The stock’s intraday volume of 1.8 million shares was 0.7 times the 3-month daily average, suggesting a moderate level of participation. The price action reflects a strong reversal from its 52-week low of $6.41 to a new high above $19.45. Despite the rally, the company remains unprofitable with a trailing twelve-month (TTM) net margin of -6.8% and an EPS of -0.40. Its market cap is $2.2 billion, with revenue up 11.2% TTM. The stock’s beta of 1.73 indicates it is more volatile than the broader market.

What To Watch

The stock is currently printing fresh 52-week highs. Investors should monitor the company’s next earnings report if scheduled, as well as any further analyst commentary or regulatory updates that could impact its trajectory.